Skip to main content
. 2016 Oct 10;2:16062. doi: 10.1038/cddiscovery.2016.62

Figure 3.

Figure 3

Flow cytometry (FACS analysis) of Jurkat cells treated with (a) 0.5 μM staurosporine or (b) 50 μM etoposide. In (c), treatments for 24 h were (1) 10 μM rapamycin; (2) 50 μM etoposide; (3) 50 μM etoposide plus pan caspase inhibitor z-VAD-fmk; (4) 15 ng/ml TRAIL; (5) 15 ng/ml TRAIL plus z-VAD-fmk; (6) untreated. (ac) ■, Annexin V-positive; ■, Annexin V-positive and mAb2C4:AF568-positive; ■, mAb2C4:AF568-positive and ■; double-negative, viable cells.